Could valproic acid be an effective anticancer agent? The evidence so far

Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer

(2014) Hyunseok Kang et al.   CANCER

Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer

(2014) S. A. Brodie et al.   Cancer Prevention Research

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

(2013) Gerald S. Falchook et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

(2012) B. F. Chu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells

(2012) Eva Juengel et al.   CANCER LETTERS

Cancer risk in people with epilepsy using valproate-sodium

(2011) G. Singh et al.   ACTA NEUROLOGICA SCANDINAVICA

A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

(2011) T. A. Mohammed et al.   ONCOLOGIST

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

(2010) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

(2010) Jaime Coronel et al.   MEDICAL ONCOLOGY

Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study

(2009) J. Hallas et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

(2009) A. I. Daud et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY